PharmaEssentia revenue and financials
$1,210.00Change from previous close: +2.98%Absolute change: +$35.00
In the fiscal year ended December 2025, PharmaEssentia reported revenue of $15.63B (+60.61% year over year). Net income was $5.05B, a net margin of 32.3%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +60.61%
- 2025 vs 2024
- Net income growth
- +70.13%
- 2025 vs 2024
- Net margin
- 32.3%
- 2024: 30.5%
Financial data
Amounts in millions of TWD; per-share values in TWD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 5,278 | 2,525 | -710 | -1,505 | — |
| Depreciation and amortization | 399 | 368 | 269 | 228 | — |
| Capital expenditure | -1,924 | -903 | -1,328 | -321 | — |
| Investing cash flow | -2,475 | -1,335 | -487 | -1,243 | — |
| Financing cash flow | -500 | -163 | 10,454 | 9,579 | — |
| Dividends paid | -366 | — | — | — | — |
| Share repurchases | — | 0.0 | -2,718 | 0.0 | -87.5 |
| Debt issued | 2,243 | 0.0 | 1.0 | 974 | — |
| Debt repaid | -2,254 | -33.4 | -986 | -12.0 | — |
| Effect of exchange rates | -661 | 358 | 104 | 19.0 | — |
| Net change in cash | 2,303 | 1,027 | 9,258 | 6,831 | — |
| Free cash flow | 3,354 | 1,621 | -2,037 | -1,826 | — |